Dr. Sonia Davila is the Executive Director of Translational Medicine at Sidra Medicine, a position she has held since December 2023. In this capacity, Dr. Davila leads the Translational Medicine Unit, overseeing all research programs and their implementation in clinical settings.

Dr. Davila’s research interests and expertise encompass infectious and immune-related diseases, as well as rare conditions such as Kawasaki and meningococcal disease.

Prior to joining Sidra Medicine, Dr. Davila was a Deputy Director at the SingHealth Duke-NUS Institute of Precision Medicine (PRISM). She also served as the Research Director at the organization’s Genomic Medicine Centre from 2019 to 2023.

Dr. Davila also previously worked as a Principal Investigator at the Genome Institute of Singapore, where she specialized on human genetic susceptibility to infectious diseases and genetic mutations associated with immune-related disorders.

Dr Davila completed her Graduate Studies in Human genetics from the University of Santiago de Compostela in Spain, where she identified novel mutations in genes causing autosomal dominant polycystic kidney disease unique to Spanish families.

She continued her postdoctoral research at Yale University, leading the discovery of two human genes causing Polycystic Liver Disease (PLD).

Dr. Davila has authored over 70 peer-reviewed publications, which have collectively received more than 10,000 citations, including articles in leading scientific journals.

Sonia Davila is contributing to the advancement of genomic medicine and precision medicine as a practical clinical tool capable of benefitting patients across the globe—no matter how rare their disease.